Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ

Watchlist Manager
Eckert & Ziegler Strahlen und Medizintechnik AG Logo
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Watchlist
Price: 39.88 EUR 7.84% Market Closed
Market Cap: 831.3m EUR
Have any thoughts about
Eckert & Ziegler Strahlen und Medizintechnik AG?
Write Note

Eckert & Ziegler Strahlen und Medizintechnik AG
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Eckert & Ziegler Strahlen und Medizintechnik AG
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Eckert & Ziegler Strahlen und Medizintechnik AG
XETRA:EUZ
Long-Term Debt
€42.7m
CAGR 3-Years
32%
CAGR 5-Years
23%
CAGR 10-Years
12%
Carl Zeiss Meditec AG
XETRA:AFX
Long-Term Debt
€217m
CAGR 3-Years
4%
CAGR 5-Years
6%
CAGR 10-Years
34%
Stratec SE
XETRA:SBS
Long-Term Debt
€93.6m
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
33%
Siemens Healthineers AG
XETRA:SHL
Long-Term Debt
€14.4B
CAGR 3-Years
5%
CAGR 5-Years
226%
CAGR 10-Years
N/A
Draegerwerk AG & Co KGaA
XETRA:DRW8
Long-Term Debt
€254.5m
CAGR 3-Years
10%
CAGR 5-Years
16%
CAGR 10-Years
4%
Sartorius AG
XETRA:SRT
Long-Term Debt
€4.4B
CAGR 3-Years
36%
CAGR 5-Years
37%
CAGR 10-Years
26%
No Stocks Found

Eckert & Ziegler Strahlen und Medizintechnik AG
Glance View

Market Cap
831.3m EUR
Industry
Health Care

Eckert & Ziegler Strahlen- und Medizintechnik AG engages in the provision of isotope technology for medical, scientific, and industrial use. The company is headquartered in Berlin, Berlin and currently employs 866 full-time employees. The company went IPO on 2008-02-25. The firm operates through three segments: Radiation Therapy, Isotope Products and Radiopharma. The Radiation Therapy segment operates through Eckert & Ziegler BEBIG and produces and distributes medical products for the treatment of cancer using brachytherapy. The Isotope Products segment provides sealed and unsealed radiation sources for medical imaging, industrial gauging, measurement and analysis, reference, calibration and environmental monitoring sources and solutions, as well as bulk radioisotopes for pharmaceutical, therapeutic and industrial product manufacturers. The Radiopharma segment specializes in molecular imaging and nuclear medicine, and supplies various radiopharmaceuticals, radiochemicals and related equipment.

EUZ Intrinsic Value
56.66 EUR
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Long-Term Debt?
Long-Term Debt
42.7m EUR

Based on the financial report for Sep 30, 2024, Eckert & Ziegler Strahlen und Medizintechnik AG's Long-Term Debt amounts to 42.7m EUR.

What is Eckert & Ziegler Strahlen und Medizintechnik AG's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
12%

Over the last year, the Long-Term Debt growth was -5%. The average annual Long-Term Debt growth rates for Eckert & Ziegler Strahlen und Medizintechnik AG have been 32% over the past three years , 23% over the past five years , and 12% over the past ten years .

Back to Top